Apexion Health Vaginal Estradiol cream
WOMEN'S HEALTHLOCALIZED THERAPY

MONTHLY SUPPLY · TOPICAL CREAM

VAGINAL ESTRADIOL

TREATMENT

Localized estrogen for vaginal health and comfort

SUPPORT

Vaginal estradiol cream delivers low-dose 17β-estradiol directly to vaginal tissue to restore epithelial thickness, lubrication, and elasticity in genitourinary syndrome of menopause (GSM) — with minimal systemic absorption at recommended doses.

Shop Now

Lab-Tested · Physician-Supervised · Discreet Delivery

Apexion Health — WOMEN'S HEALTH

RESTORE VAGINAL HEALTH WHERE IT MATTERS MOST.

Genitourinary syndrome of menopause (GSM) — formerly called vaginal atrophy — affects up to 60% of postmenopausal women and causes vaginal dryness, dyspareunia, recurrent urinary tract infections, and urinary urgency. Unlike systemic estrogen therapy, vaginal estradiol cream is applied locally at low doses, restoring the estrogen-dependent vaginal epithelium, supporting lactobacillus colonization, and reducing vaginal pH — with systemic absorption remaining near-undetectable at standard dosing.

Clinical Benefits

VAGINAL ESTRADIOL SUPPORTS YOUR HEALTH AT THE CELLULAR LEVEL

  1. 01.

    RESTORES VAGINAL EPITHELIAL THICKNESS AND MOISTURE

  2. 02.

    REDUCES DYSPAREUNIA (PAIN WITH INTERCOURSE)

  3. 03.

    NORMALIZES VAGINAL PH TO SUPPORT HEALTHY FLORA

  4. 04.

    REDUCES RISK OF RECURRENT URINARY TRACT INFECTIONS

  5. 05.

    MINIMAL SYSTEMIC ABSORPTION AT RECOMMENDED DOSES

  6. 06.

    PHYSICIAN-PRESCRIBED LOCALIZED BIOIDENTICAL FORMULATION

Shop Now

Clinical Evidence

How It Works in the Body

01 — Dose & Efficacy

Genitourinary Syndrome Treatment

Vaginal pH Normalization in 12 weeks90%
Maturation Index Superficial cells 8%→42%80%
Symptom Improvement Relief of dryness & pain85%

Bachmann et al., Obstet Gynecol 2008; NAMS 2020

02 — Hormone Panel

Vaginal Tissue Biomarkers

MarkerWithoutWith Treatment
Vaginal pHpH
6.0
4.5−1.5
VMI (% Superficial)%
8
42+34
Dyspareunia SeverityVAS
7.5
1.5−6.0
Vaginal DrynessVAS
7.0
1.0−6.0

Minimal systemic absorption — endometrial protection NOT required

Low-dose vaginal E2 (<10 mcg tablet, <0.5 mg cream, 7.5 mcg/day ring) produces local effects with negligible serum E2 elevation. Safe for women who cannot use systemic HRT. No progestogen needed.

Bachmann et al., Obstet Gynecol 2008; Suckling et al., Cochrane 2006

03 — Protocol

Local Vaginal Estradiol Treatment

LoadingWeeks 1–2
  • ›Estradiol 10 mcg tablet daily OR 0.5 mg cream daily
  • ›Symptom baseline
  • ›Vaginal pH at exam
RestorationWeeks 3–12
  • ›Daily tablet OR 2–3×/week cream
  • ›Symptom diary
  • ›pH & clinical assessment at 12 weeks
MaintenanceMonth 4+
  • ›Reduce to 2×/week tablet OR 1×/week cream
  • ›Symptom check q6 months
  • ›No endometrial surveillance needed

Local therapy — no systemic risks, no progestogen

Full tissue effect takes 8–12 weeks. Ring (7.5 mcg/day) and 10 mcg tablets have most favorable safety data. Symptoms improve within 2–4 weeks. Safe for long-term use.

All protocols physician-supervised and adjusted per individual labs.